2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetic acid | 1878-59-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetic acid
• 英文别名: 2-[(5,6,7,8-tetrahydronaphthalen-2-yl)oxy]acetic acid；(5,6,7,8-Tetrahydronaphthalen-2-yl)oxyacetic acid；(5,6,7,8-tetrahydro-[2]naphthyloxy)-acetic acid；O-(5.6.7.8-Tetrahydro-naphthyl-(2))-glykolsaeure；(5,6,7,8-Tetrahydro-[2]naphthyloxy)-essigsaeure；<5,6,7,8-Tetrahydro-naphthyl-(2)-oxy>-essigsaeure；(5,6,7,8-Tetrahydro-naphthalen-2-yloxy)-acetic acid；2-(5,6,7,8-tetrahydronaphthalen-2-yloxy)acetic acid
• CAS: 1878-59-7
• 化学式: C₁₂H₁₄O₃
• mdl: MFCD03145115
• 分子量: 206.241
• InChiKey: WCKYBLCGUSVWQI-UHFFFAOYSA-N

物化性质

• 沸点：
  376.9±37.0 °C(Predicted)
• 密度：
  1.203±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetic acid 在 sodium hydroxide 、 硫酸 、 一水合肼 作用下， 以 乙醇 、 水 为溶剂， 反应 9.0h， 生成 3-[(5,6,7,8-Tetrahydronaphthalen-2-yl)oxymethyl]-4-phenyl-5-mercapto-1,2,4-triazole
  参考文献：
  名称：

  Synthesis and analgesic activity of some triazoles and triazolothiadiazines

  摘要：

  The synthesis of some triazoles and triazolothiadiazines starting from (5,6,7,8-tetrahydronaphthalen-2-yl)oxyacetic acid is described. The chemical structure of the compounds were elucidated by analytical, IR, H-1 NMR and mass spectral studies. Some of the newly synthesized compounds were tested for analgesic activity and compounds 5b, 5c, and 5d exhibited promising analgesic activity. (C) 1999 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(99)00016-6
• 作为产物：
  描述：

  5,6,7,8-四氢-2-萘酚 在 lithium hydroxide monohydrate 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetic acid
  参考文献：
  名称：

  [EN] CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS
  [FR] COMPOSÉS CHIMIQUES UTILISÉS COMME INHIBITEURS DE LA VOIE ATF4

  摘要：

  这项发明涉及取代的桥环脂环烷衍生物。具体而言，该发明涉及符合以下式（IIIQ）的化合物：其中X6'，a，b，C8'，D8'，L82'，L83'，R81'，R82'，R83'，R84'，R85'，R86'，z82'，z84'，z85'和z86'如本文所定义；或其盐。该发明的化合物是ATF4途径的抑制剂。因此，该发明进一步涉及包括该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包括该发明化合物的药物组合物抑制ATF4途径和治疗相关疾病的方法。

  公开号：

  WO2018225093A1

文献信息

• Discovery and development of a novel class of phenoxyacetyl amides as highly potent TRPM8 agonists for use as cooling agents
  作者：Alain Noncovich、Chad Priest、Jane Ung、Andrew P. Patron、Guy Servant、Paul Brust、Nicole Servant、Nathan Faber、Hanghui Liu、Nicole S. Gonsalves、Tanya L. Ditschun

  DOI：10.1016/j.bmcl.2017.04.003

  日期：2017.8

  The paper presents the activity trends for a novel series of phenoxyacetyl amides as human TRPM8 receptor agonists. This series encompasses in vitro activity values ranging from the micromolar to the picomolar levels. Sensory evaluation of these molecules highlights their relevance as cooling agents for oral applications. The positive outcome of the complete evaluation of N-(1H-pyrazol-3-yl)-N-(th

  本文介绍了一系列新型的苯氧基乙酰酰胺作为人类TRPM8受体激动剂的活性趋势。该系列涵盖了从微摩尔到皮摩尔水平的体外活性值。这些分子的感官评估突显了它们作为口腔用清凉剂的重要性。对N-（1H-吡唑-3-基）-N-（噻吩-2-基甲基）-2-（对甲苯氧基）乙酰胺进行全面评估的积极结果导致批准了公认的安全（GRAS）调味品和提取物制造商协会（FEMA）的状态为FEMA 4809。
• Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors
  作者：Mehlika Dilek Altıntop、Belgin Sever、Gülşen Akalın Çiftçi、Gülhan Turan-Zitouni、Zafer Asım Kaplancıklı、Ahmet Özdemir

  DOI：10.1016/j.ejmech.2018.06.049

  日期：2018.7

  current work, new 1,3,4-oxadiazole derivatives were synthesized and investigated for their cytotoxic effects on A549 human lung adenocarcinoma, C6 rat glioma and NIH/3T3 mouse embryonic fibroblast cell lines. Compounds 2, 6 and 9 were found to be the most potent anticancer agents against A549 and C6 cell lines and therefore their effects on apoptosis, caspase-3 activation, Akt, FAK, mitochondrial membrane

  在当前的工作中，合成了新的1,3,4-恶二唑衍生物，并研究了它们对A549人肺腺癌，C6大鼠神经胶质瘤和NIH / 3T3小鼠胚胎成纤维细胞系的细胞毒性作用。化合物2，6和9被认为是针对A549和C6细胞系，因此它们对细胞凋亡的影响的最有效的抗癌剂，胱天蛋白酶-3激活，Akt的，FAK，线粒体膜电位和超微结构形态变化进行了评价。N-（5-硝基噻唑-2-基）-2-[[5-[（（5,6,7,8-四氢萘-2-基）氧基）甲基] -1,3,4-恶二唑-2- [基]硫代]乙酰胺（9）与顺铂相比，A549和C6细胞的早期和晚期凋亡细胞总数增加更多，并且导致两种细胞系中的线粒体膜去极化作用均高于顺铂。另一方面，N-（6-甲氧基苯并噻唑-2-基）-2-[[5-[（（5,6,7,8-四氢萘-2-基）氧基）甲基] -1,3,4在两种细胞系中，-oxadiazol-2-yl] thio]乙酰胺（6）引起的casp
• Acyl dipeptides as reversible caspase inhibitors. Part 1: Initial Lead Optimization
  作者：Steven D. Linton、Donald S. Karanewsky、Robert J. Ternansky、Joe C. Wu、Brian Pham、Lalitha Kodandapani、Robert Smidt、Jose-Luis Diaz、Lawrence C. Fritz、Kevin J. Tomaselli

  DOI：10.1016/s0960-894x(02)00629-7

  日期：2002.10

  Parallel synthesis was used to explore the SAR of a peptidomimetic caspase inhibitor. The most potent compound had nanomolar activity against caspases 1, 3, 6, 7, and 8. (C) 2002 Elsevier Science Ltd. All rights reserved.
• Templeman; Sexton, Proceedings of the Royal Society of London. Series B, Biological sciences, 1946, vol. 133, p. 300,306
  作者：Templeman、Sexton

  DOI：——

  日期：——
• Chemical Compounds as ATF-4 Pathway Inhibitors
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20210093619A1

  公开（公告）日：2021-04-01

  The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula IIIQ: wherein X 6′ , a, b, C 8′ , D 8′ , L 82′ , L 83′ , R 81′ , R 82′ , R 83′ , R 84′ , R 85′ , R 86′ , z 82′ , z 84′ , z 85′ , and z 86′ are as defined herein; or salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.